Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Billings Clinic

Neither a doctor nor a teaching hospital

Research payments

$663,759

19 payments

Through program year 2025, Billings Clinic is reported as receiving $663,759 in research payments, across 19 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $141,354 1
2024 Research $196,465 1
2023 Research $275,544 2
2022 Research $750 1
2020 Research $925 1
2019 Research $48,722 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $613,363 4 payments
  2. Novo Nordisk AS $27,753 9 payments
  3. Biogen, Inc. $13,125 2 payments
  4. Amicus Therapeutics, Inc. $5,853 1 payment
  5. Bayer HealthCare Pharmaceuticals Inc. $2,000 1 payment
  6. Amgen Inc. $925 1 payment
  7. AstraZeneca UK Limited $740 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $613,363 4 payments
  2. Nn9068-4228 $21,557 2 payments
  3. Dimethyl Fumarate (DMF) Observational Study $12,375 1 payment
  4. Nn9924-4257 $6,196 7 payments
  5. PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD $5,853 1 payment
  6. 060204 - Clinical Trial Pase IV (Post Marketing) (Bayer Product or TA) $2,000 1 payment
  7. Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) $925 1 payment
  8. A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) $750 1 payment
  9. A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck $740 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record